Lactobacillus delbrueckii bulgaricus + Streptococcus thermophilus & Non-Alcoholic Fatty Liver Disease (NAFLD) / Metabolic dysfunction-associated fatty liver disease (MAFLD)

Clinical data

The double blind randomized clinical trial XXX - Lactobacillus delbrueckii bulgaricus + Streptococcus thermophilus & Non-Alcoholic Fatty Liver Disease (NAFLD) / Metabolic dysfunction-associated fatty liver disease (MAFLD) revealed that a tablet containing 500 million Lactobacillus delbrueckii bulgaricus + Streptococcus thermophilus improved liver aminotransferase levels in patients with Non-Alcoholic Fatty Liver Disease (NAFLD) / Metabolic dysfunction-associated fatty liver disease (MAFLD) (1)

References

(1) Aller et al. 2011 Eur. Rev. Med. Pharm. Sci. 15: 1090–1095

see also:
[Non-Alcoholic Fatty Liver Disease (NAFLD) / Metabolic dysfunction-associated fatty liver disease (MAFLD) & Drugs/…